ArticleBioinformatics advances2026
ULSL: Unified Latent and Similarity Learning for robust multi-omics cancer subtype identification.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Cancer's high heterogeneity necessitates precise molecular classification for improved clinical outcomes. However, current multi-omics clustering often struggles with molecular complexity. We propose Unified Latent and Similarity Learning (ULSL), a novel framework that simultaneously learns latent embeddings and similarity matrices through unified optimization. ULSL employs graph fusion for cross-omics structural consistency and latent representation learning to project data into low-dimensional spaces, effectively mitigating noise and high dimensionality. Results: ULSL was evaluated on synthetic datasets and 10 public cancer datasets from The Cancer Genome Atlas (TCGA). It consistently outperformed seven state-of-the-art methods in accuracy and robustness for subtype identification. On simulated datasets, ULSL maintained superior performance even with weak signal features and high noise levels. On TCGA datasets, ULSL not only identified survival-associated subtypes in a larger number of cancer types but also detected a greater number of clinically enriched features compared to competing approaches. Furthermore, the specific case study on AML demonstrated that ULSL aligns with the biological basis of the traditional FAB classification while offering distinct advantages in prognostic stratification. Availability and implementation: The source code for ULSL is available at https://github.com/codelzy-01/ULSL-1.git.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.